Vanderbilt researchers have developed a set of nanoparticles that stimulate the immune system in mice to combat most cancers and will ultimately do the identical in people.
The analysis, led by John T. Wilson, affiliate professor of chemical and biomolecular engineering and biomedical engineering, was just lately revealed in ACS Nano.
Working with collaborators at Yale College, Wilson and his staff designed lipid nanoparticles—the tiny balls of fats behind the success of mRNA vaccines—to ship a nucleic acid molecule that triggers an anti-tumor immune response.
The nucleic acid stimulates the retinoic acid inducible gene I, or RIG-I, pathway that’s usually utilized by the physique to acknowledge international viruses, akin to influenza, to assist the immune system mount a protection, in response to the researchers.
By packaging this molecule into lipid nanoparticles to enhance its supply to the cytosol of cells, the researchers had been capable of strongly activate the RIG-I pathway, triggering the immune system to focus its consideration on killing most cancers cells in mouse fashions of breast most cancers and melanoma.
“RIG-I is usually activated to assist the physique fight viral infections and there may be compelling proof that this identical pathway could be harnessed to stimulate the immune system to combat most cancers,” stated Wilson, a Chancellor College Fellow.
Whereas a lot work stays earlier than such expertise could be superior to deal with human cancers, the authors famous that lipid nanoparticles have already been administered to hundreds of thousands of people that have obtained the COVID-19 mRNA vaccine and that different medication that activate RIG-I’ve superior into medical trials, creating a possible path to medical testing.
“We noticed very good responses even with out doing numerous optimization to the system, and so this units the stage for future work to develop applied sciences that may do that much more successfully and in addition safely,” Wilson stated.
Extra info: Lihong Wang-Bishop et al, Nanoparticle Retinoic Acid-Inducible Gene I Agonist for Most cancers Immunotherapy, ACS Nano (2024). DOI: 10.1021/acsnano.3c06225
Supplied by Vanderbilt College